Biohazard? Gilead Leads 5 Big-Cap Biotech Earnings

By | April 18, 2014

Scalper1 News

Can biotech stocks bounce back? As recently as last month, the Medical-Biomed/Biotech group was ranked No. 1 out of IBD’s 197 industries. But it’s been dead last over the last four weeks, plunging 22.1%. That partly reflects growth stocks overall falling hard in the current market correction. But specific concerns over sky-high drug prices, notably Gilead Sciences’ blockbuster hepatitis C fighter Sovaldi, have spooked investors. This coming week, Scalper1 News

Scalper1 News